Multiple recent meta-analyses covering studies that included a variety of controls, such as metformin, insulin, DPP4 inhibitors, SGLT2 inhibitors, sulfonylureas, and TZDs, demonstrated a reduction in prostate cancer incidence in men with T2D who took GLP-1R therapies (67–69). The gene discussed is GLP1R; the disease is prostate cancer.